Oxindole I is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinase Flk-1 (fetal liver kinase-1; IC50 = 390 nM). Also, to a lesser extent, it inhibits PDGFR (platelet derived growth factor receptor) kinase (IC50 = 12 μM). However, Oxindole I does not affect EGFR, HER2, and IGF-1R even at high concentrations (>100 μM). Oxindole I also inhibits cyclin D1/Cdk4 enzyme (IC50 = 4.9 μM) preferentially over cyclin E/Cdk2 (IC50 = 10 μM) and cyclin B/Cdk1 (IC50 = 10.2 μM).
1. Kent, L L., et al., 1999. Characterization of novel inhibitors of cyclin-dependent kinases. Biochemical and biophysical research communications. 260(3): 768-74. PMID: 10403840
2. Vieth, M., et al., 2000. DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors. Journal of medicinal chemistry. 43(16): 3020-32. PMID: 10956210
See how others have used Oxindole I. Click on the entry to view the PubMed entry .
PMID: # 26188358 Zhou, W. et al. 2015. Oncotarget. 6: 21557-71.
PMID: # 25186293 Soggia, A. et al. 2014. Diabetologia. 57: 2348-56.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.